Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. ABBV has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
ABBV stock price ended at $191.08 on Friday, after losing-0.7%
The AbbVie Inc stock price decreased by -0.7% on the last trading day (13 Jun 2025), dropping from 191.56 to 191.08. Throughout the last trading session, the stock experienced a fluctuation of 1.67% , ranging from a day low of $190.29 to a day high of 193.47. The price has declined in 2 of the last 10 days, resulting in a total change of 2.67% during this period. On the last day, trading volume decrease by -815.65K shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 4.97M shares were traded, amounting to approximately 949.86M.
ABBV Technical Signals
ABBV(AbbVie Inc Corp) has 5 buy signals and 4 sell signals now. The current trend is consolidation starting from 2025-05-22. The total price change during this trend is +4.68%. Recently, the price has decreased but the volume has also decreased, indicating a potential rebound signal. The average turnover of ABBV over the last 5 trading days is 893.20M. Overall, the technical indicator signals lean more toward a Neutral outlook in the mid-term.
ABBV Moving Average Analysis
AbbVie Inc's overall moving average trend leans more bullish as of Saturday, June 14, 2025, with 2 negative signals and 2 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $195.113331, and $199.0974. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $182.22246900000002, and $178.2384. A break-down below any of these levels will issue sell signals.
ABBV Short Selling Analysis
The short sale ratio of AbbVie Inc(ABBV) as of 09 Jun 2025 is 17.12%, dropping from last trading day. With decreasing price from 189.83 to 189.16. The short sell activity indicate that short sellers may be anticipating price hit a bottom.
Technical Signal
Technical Signals Summary
Sell
4
Buy
5
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
5 Bullish Signals
5 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
3.218
Bullish
Momentum (10 days)
MOM_10 > 0
4.97
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
1.2
Bullish
Moving Average
10-day SMA crosses above 60-day SMA
--
Bullish
Moving Average
10-day SMA crosses above 200-day SMA
--
Bullish
4 Bearish Signals
4 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 > 80
86
Bearish
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 > 100
126.233
Bearish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 > 80
92.284
Bearish
Moving Average
60-day SMA crosses below 200-day SMA
--
Bearish
ABBV Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to AbbVie Inc(ABBV), our algorithm predicts ABBV's 1-month price at $170.05, with an -10.42%downwardshift. Using a similarity score up to 91.97%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for AbbVie Inc (ABBV.N) stock, as of Sunday, June 8, 2025 , forecasts a -10.42% change over the next month, based on its high correlation with WLK.N stock patterns. The similarity between their price movements over the analyzed periods is 91.97%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
ABBV
No Data
WLK
Down: -10.42%Similarity: 91.97%
Name
Similarity
Up/Down
WLK.N
91.97%
-10.42%
BMY.N
91.25%
+2.77%
KELYA.O
90.44%
-4.87%
CRS.N
90.31%
-2.26%
ABBV Seasonality Analysis
Based on ABBV's historical stock price data across all years, the probability of a positive return in June is60.00%, suggesting it maybe an ideal month to invest in ABBV. In contrast,Februaryoffers the highest probability of positive returns at84.62%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying AbbVie Inc (ABBV.N) stock in February has the highest probability of a positive return (84.62%), while September has the lowest probability (38.46%).
Performance Seasonality
The chart shows AbbVie Inc. (ABBV)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy AbbVie Inc (ABBV.N) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. ABBV has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying AbbVie Inc (ABBV.N) stock in a year?
The radar chart shows that buying AbbVie Inc (ABBV.N) stock in February has the highest probability of a positive return (84.62%), while September has the lowest probability (38.46%).
How has AbbVie Inc. (ABBV)'s stock price performed over the past three years?
ABBV's stock price fell by -4.56% in 2023,increased by 11.19% in 2024, and went up by 6.49% in 2025.
Which bull technical signals does ABBV have?
Bullish technical signals of ABBV include: AO_5_34 > 0, MOM_10 > 0, MACD_12_26_9 > 0, 10-day SMA crosses above 60-day SMA, 10-day SMA crosses above 200-day SMA.
Is ABBV a buy based on overall technical signals summary?
ABBV has 5 buy signals and 4 sell signals now. Overall the technical rating for ABBV is Neutral . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of ABBV.
What is the trend of AbbVie Inc (ABBV)'s moving average?
AbbVie Inc's overall moving average trend leans more bullish as of June 14 2025, with 2 negative signals and 2 positive signal.
What is price prediction for ABBV stock next month?
The price prediction chart for AbbVie Inc (ABBV.N) stock, as of June 08 2025, forecasts a -10.42% change over the next month, based on its high correlation with WLK stock patterns. The similarity between their price movements over the analyzed periods is 91.97%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for ABBV Stock?
ABBV stock is predicted to reach **$192** by the end of 2025. This forecast is based on strong earnings, driven by Skyrizi and Rinvoq offsetting Humira's decline, and a bullish outlook from analysts.
What is price prediction 2030 for ABBV Stock?
### **Price Prediction for ABBV Stock in 2030**
Based on current trends and analysis, AbbVie (ABBV) is expected to reach a stock price of **$215 to $240** by 2030. This prediction is supported by the company's strong product portfolio, including Skyrizi and Rinvoq, which are driving revenue growth and offsetting the decline of Humira. Additionally, AbbVie's solid earnings performance and reasonable valuation metrics, such as a forward P/E ratio of 16.89, suggest continued upward momentum. Analysts also maintain a bullish outlook, with an average price target of $205, further supporting the potential for long-term growth.